[1]
|
Björkegren, J.L.M. and Lusis, A.J. (2022) Atherosclerosis: Recent Developments. Cell, 185, 1630-1645.
https://doi.org/10.1016/j.cell.2022.04.004
|
[2]
|
Yurtseven, E., Ural, D., Baysal, K. and Tokgözoğlu, L. (2020) An Update on the Role of PCSK9 in Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 27, 909-918. https://doi.org/10.5551/jat.55400
|
[3]
|
Katsuki, S., Jha, P., Lupieri, A., Nakano, T., Passos, L.S.A., Rogers, M.A., Becker-Greene, D., Le, T.D., Decano, J.L., Ho Lee, L., Guimaraes, G.C., Abdelhamid, I., Halu, A., Muscoloni, A., Can-nistraci, C., Higashi, H., Zhang, H., Vromman, A., Libby, P., Keith Ozaki, C. and Aikawa, M. (2022) Proprotein Con-vertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms. Cir-culation Research, 131, 873-889.
https://doi.org/10.1161/CIRCRESAHA.121.320056
|
[4]
|
Seidah, N.G. and Prat, A. (2012) The Biology and Ther-apeutic Targeting of the Proprotein Convertases. Nature Reviews Drug Discovery, 11, 367-383. https://doi.org/10.1038/nrd3699
|
[5]
|
Seidah, N.G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S.B., Stifani, S., Basak, A., Prat, A. and Chretien, M. (2003) The Secretory Proprotein Convertase Neural Apopto-sis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 100, 928-933. https://doi.org/10.1073/pnas.0335507100
|
[6]
|
Seidah, N.G. and Prat, A. (2007) The Proprotein Convertases Are Potential Targets in the Treatment of Dyslipidemia. Journal of Molecular Medicine (Berlin), 85, 685-696. https://doi.org/10.1007/s00109-007-0172-7
|
[7]
|
Seidah, N.G. (2011) The Proprotein Convertases, 20 Years Later. Methods in Molecular Biology, 768, 23-57.
https://doi.org/10.1007/978-1-61779-204-5_3
|
[8]
|
Schulz, R., Schlüter, K.D. and Laufs, U. (2015) Molecular and Cellular Function of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Basic Research in Cardiology, 110, Article No. 4.
https://doi.org/10.1007/s00395-015-0463-z
|
[9]
|
Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A.D., Rader, D.J., Boileau, C., Brissette, L., Chrétien, M., Prat, A. and Seidah, N.G. (2004) NARC-1/PCSK9 and Its Natural Mutants: Zymogen Cleavage and Effects on the Low Density Lipoprotein (LDL) Receptor and LDL Cholesterol. The Journal of Biological Chemistry, 279, 48865-48875.
https://doi.org/10.1074/jbc.M409699200
|
[10]
|
Tao, R., Xiong, X., DePinho, R.A., Deng, C.X. and Dong, X.C. (2013) FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-Cholesterol Home-ostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression. The Journal of Bio-logical Chemistry, 288, 29252-29259.
https://doi.org/10.1074/jbc.M113.481473
|
[11]
|
Leren, T.P. (2004) Mutations in the PCSK9 Gene in Norwegian Subjects with Autosomal Dominant Hypercholesterolemia. Clinical Genetics, 65, 419-422. https://doi.org/10.1111/j.0009-9163.2004.0238.x
|
[12]
|
Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K. and Hobbs, H.H. (2005) Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Nonsense Mutations in PCSK9. Nature Genetics, 37, 161-165.
https://doi.org/10.1038/ng1509
|
[13]
|
中华医学会外科学分会血管外科学组. 颈动脉狭窄诊治指南[J]. 中国血管外科杂志(电子版), 2017, 9(3): 169-175. https://doi.org/10.3969/j.issn.1674-7429.2017.03.003
|
[14]
|
Gui, Y., Zheng, H. and Cao, R.Y. (2022) Foam Cells in Atherosclerosis: Novel Insights Into Its Origins, Consequences, and Molecular Mechanisms. Frontiers in Cardiovascular Medicine, 9, Article ID: 845942.
https://doi.org/10.3389/fcvm.2022.845942
|
[15]
|
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., Lisheng, L. and INTERHEART Study Investigators (2004) Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the INTERHEART Study): Case-Control Study. The Lancet (London, England), 364, 937-952. https://doi.org/10.1016/S0140-6736(04)17018-9
|
[16]
|
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R.J. and Okopień, B. (2022) Insight into the Evolving Role of PCSK9. Metabolites, 12, Article No. 256.
https://doi.org/10.3390/metabo12030256
|
[17]
|
Xia, X.D., Peng, Z.S., Gu, H.M., Wang, M., Wang, G.Q. and Zhang, D.W. (2021) Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. Fron-tiers in Cardiovascular Medicine, 8, Article ID: 764038.
https://doi.org/10.3389/fcvm.2021.764038
|
[18]
|
Levy, E., Ben Djoudi Ouadda, A., Spahis, S., Sane, A.T., Garofa-lo, C., Grenier, É., Emonnot, L., Yara, S., Couture, P., Beaulieu, J.F., Ménard, D., Seidah, N.G. and Elchebly, M. (2013) PCSK9 Plays a Significant Role in Cholesterol Homeostasis and Lipid Transport in Intestinal Epithelial Cells. Athero-sclerosis, 227, 297-306.
https://doi.org/10.1016/j.atherosclerosis.2013.01.023
|
[19]
|
Fernández-Friera, L., Fuster, V., López-Melgar, B., Oli-va, B., Sánchez-González, J., Macías, A., Pérez-Asenjo, B., Zamudio, D., Alonso-Farto, J.C., España, S., Mendiguren, J., Bueno, H., García-Ruiz, J.M., Ibañez, B., Fernández-Ortiz, A. and Sanz, J. (2019) Vascular Inflammation in Subclin-ical Atherosclerosis Detected by Hybrid PET/MRI. Journal of the American College of Cardiology, 73, 1371-1382. https://doi.org/10.1016/j.jacc.2018.12.075
|
[20]
|
Cheng, J.M., Oemrawsingh, R.M., Garcia-Garcia, H.M., Boersma, E., van Geuns, R.J., Serruys, P.W., Kardys, I. and Akkerhuis, K.M. (2016) PCSK9 in Relation to Coronary Plaque In-flammation: Results of the ATHEROREMO-IVUS Study. Atherosclerosis, 248, 117-122. https://doi.org/10.1016/j.atherosclerosis.2016.03.010
|
[21]
|
Swirski, F.K., Libby, P., Aikawa, E., Alcaide, P., Lus-cinskas, F.W., Weissleder, R. and Pittet, M.J. (2007) Ly-6Chi Monocytes Dominate Hypercholesterolemia-Associated Monocytosis and Give Rise to Macrophages in Atheromata. The Journal of Clinical Investigation, 117, 195-205. https://doi.org/10.1172/JCI29950
|
[22]
|
Giunzioni, I., Tavori, H., Covarrubias, R., Major, A.S., Ding, L., Zhang, Y., DeVay, R.M., Hong, L., Fan, D., Predazzi, I.M., Rashid, S., Linton, M.F. and Fazio, S. (2016) Local Effects of Human PCSK9 on the Atherosclerotic Lesion. The Journal of Pathology, 238, 52-62. https://doi.org/10.1002/path.4630
|
[23]
|
Tang, Z.H., Peng, J., Ren, Z., Yang, J., Li, T.T., Li, T.H., Wang, Z., Wei, D.H., Liu, L.S., Zheng, X.L. and Jiang, Z.S. (2017) New Role of PCSK9 in Atherosclerotic Inflammation Promotion Involving the TLR4/NF-κB Pathway. Atherosclerosis, 262, 113-122. https://doi.org/10.1016/j.atherosclerosis.2017.04.023
|
[24]
|
Ricci, C., Ruscica, M., Camera, M., Rossetti, L., Macchi, C., Colciago, A., Zanotti, I., Lupo, M.G., Adorni, M.P., Cicero, A.F.G., Fogacci, F., Corsini, A. and Ferri, N. (2018) PCSK9 Induces a Pro-Inflammatory Response in Macrophages. Scientific Reports, 8, Article No. 2267. https://doi.org/10.1038/s41598-018-20425-x
|
[25]
|
Ding, Z., Pothineni, N.V.K., Goel, A., Lüscher, T.F. and Mehta, J.L. (2020) PCSK9 and Inflammation: Role of Shear Stress, Pro-Inflammatory Cytokines, and LOX-1. Cardiovascular Research, 116, 908-915.
https://doi.org/10.1093/cvr/cvz313
|
[26]
|
Udaya, R. and Sivakanesan, R. (2022) Synopsis of Biomarkers of Ather-omatous Plaque Formation, Rupture and Thrombosis in the Diagnosis of Acute Coronary Syndromes. Current Cardiol-ogy Reviews, 18, 53-62.
https://doi.org/10.2174/1573403X18666220411113450
|
[27]
|
Ding, Z., Wang, X., Liu, S., Shahanawaz, J., Theus, S., Fan, Y., Deng, X., Zhou, S. and Mehta, J.L. (2022) Corrigendum to: PCSK9 Regulates Expression of Scavenger Re-ceptors and ox-LDL Uptake in Macrophages. Cardiovascular Research, 118, 1849. https://doi.org/10.1093/cvr/cvab354
|
[28]
|
Wu, N.Q., Shi, H.W. and Li, J.J. (2022) Proprotein Convertase Subtil-isin/Kexin Type 9 and Inflammation: An Updated Review. Frontiers in Cardiovascular Medicine, 9, Article ID: 763516. https://doi.org/10.3389/fcvm.2022.763516
|
[29]
|
Li, J., Liang, X., Wang, Y., Xu, Z. and Li, G. (2017) Investigation of Highly Expressed PCSK9 in Atherosclerotic Plaques and ox-LDL-Induced Endothelial Cell Apoptosis. Molecular Medicine Reports, 16, 1817-1825.
https://doi.org/10.3892/mmr.2017.6803
|
[30]
|
Shapiro, M.D. and Fazio, S. (2017) PCSK9 and Atherosclero-sis—Lipids and Beyond. Journal of Atherosclerosis and Thrombosis, 24, 462-472. https://doi.org/10.5551/jat.RV17003
|
[31]
|
Ruscica, M., Tokgözoğlu, L., Corsini, A. and Sirtori, C.R. (2019) PCSK9 Inhibition and Inflammation: A Narrative Review. Atherosclerosis, 288, 146-155. https://doi.org/10.1016/j.atherosclerosis.2019.07.015
|
[32]
|
Denis, C.V. and Wagner, D.D. (2007) Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 728-739.
https://doi.org/10.1161/01.ATV.0000259359.52265.62
|
[33]
|
van der Meijden, P.E.J. and Heemskerk, J.W.M. (2019) Platelet Biology and Functions: New Concepts and Clinical Perspectives. Nature Reviews Cardiology, 16, 166-179. https://doi.org/10.1038/s41569-018-0110-0
|
[34]
|
Camera, M., Rossetti, L., Barbieri, S.S., Zanotti, I., Can-ciani, B., Trabattoni, D., Ruscica, M., Tremoli, E. and Ferri, N. (2018) PCSK9 as a Positive Modulator of Platelet Activa-tion. Journal of the American College of Cardiology, 71, 952-954. https://doi.org/10.1016/j.jacc.2017.11.069
|
[35]
|
Barale, C., Bonomo, K., Frascaroli, C., Morotti, A., Guerrasio, A., Cavalot, F. and Russo, I. (2020) Platelet Function and Activation Markers in Primary Hypercholesterolemia Treated with Anti-PCSK9 Monoclonal Antibody: A 12-Month Follow-Up. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD, 30, 282-291.
https://doi.org/10.1016/j.numecd.2019.09.012
|
[36]
|
Cammisotto, V., Pastori, D., Nocella, C., Bartimoccia, S., Cas-tellani, V., Marchese, C., Scavalli, A.S., Ettorre, E., Viceconte, N., Violi, F., Pignatelli, P. and Carnevale, R. (2020) PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. Antioxidants (Basel, Switzerland), 9, Article No. 296.
https://doi.org/10.3390/antiox9040296
|
[37]
|
Qi, Z., Hu, L., Zhang, J., Yang, W., Liu, X., Jia, D., Yao, Z., Chang, L., Pan, G., Zhong, H., Luo, X., Yao, K., Sun, A., Qian, J., Ding, Z. and Ge, J. (2021) PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation, 143, 45-61.
https://doi.org/10.1161/CIRCULATIONAHA.120.046290
|
[38]
|
Barale, C., Melchionda, E., Morotti, A. and Russo, I. (2021) PCSK9 Biology and Its Role in Atherothrombosis. International Journal of Molecular Sciences, 22, Article No. 5880. https://doi.org/10.3390/ijms22115880
|
[39]
|
Rhainds, D., Arsenault, B.J. and Tardif, J.-C. (2012) PCSK9 In-hibition and LDL Cholesterol Lowering: The Biology of an Attractive Therapeutic Target and Critical Review of the Lat-est Clinical Trials. Clinical Lipidology, 7, 621-640.
https://doi.org/10.2217/clp.12.74
|
[40]
|
Traynor, K. (2015) Evolocumab Approved for Reducing LDL Cholesterol. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Phar-macists, 72, 1599-1600.
https://doi.org/10.2146/news150066
|
[41]
|
Hadjiphilippou, S. and Ray, K.K. (2017) Evolocumab and Clinical Out-comes in Patients with Cardiovascular Disease. The Journal of the Royal College of Physicians of Edinburgh, 47, 153-155. https://doi.org/10.4997/JRCPE.2017.212
|
[42]
|
Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., El Shahawy, M., Koren, M.J., Lepor, N.E., Lorenzato, C., Pordy, R., Chaudhari, U., Kastelein, J.J. and ODYSSEY LONG TERM Investigators (2015) Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. The New England Journal of Medicine, 372, 1489-1499. https://doi.org/10.1056/NEJMoa1501031
|
[43]
|
Schwartz, G.G., Steg, P.G., Szarek, M., Bhatt, D.L., Bittner, V.A., Diaz, R., Edelberg, J.M., Goodman, S.G., Hanotin, C., Harrington, R.A., Jukema, J.W., Lecorps, G., Mahaffey, K.W., Moryusef, A., Pordy, R., Quintero, K., Roe, M.T., Sasiela, W.J., Tamby, J.F., Tricoci, P. and ODYSSEY OUTCOMES Committees and Investigators (2018) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine, 379, 2097- 2107. https://doi.org/10.1056/NEJMoa1801174
|
[44]
|
Toth, P.P., Worthy, G., Gandra, S.R., Sattar, N., Bray, S., Cheng, L.I., Bridges, I., Worth, G.M., Dent, R., Forbes, C.A., Desh-pande, S., Ross, J., Kleijnen, J. and Stroes, E.S.G. (2017) Systematic Review and Network Meta-Analysis on the Effi-cacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. Journal of the Ameri-can Heart Association, 6, e005367. https://doi.org/10.1161/JAHA.116.005367
|
[45]
|
Ray, K.K., Landmesser, U., Leiter, L.A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R.P., Turner, T., Visseren, F.L., Wijngaard, P., Wright, R.S. and Kastelein, J.J. (2017) Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. The New England Journal of Medicine, 376, 1430-1440.
https://doi.org/10.1056/NEJMoa1615758
|
[46]
|
Kosmas, C.E., Muñoz Estrella, A., Sourlas, A., Silverio, D., Hilario, E., Montan, P.D. and Guzman, E. (2018) Inclisiran: A New Promising Agent in the Management of Hypercholesterole-mia. Diseases (Basel, Switzerland), 6, Article No. 63. https://doi.org/10.3390/diseases6030063
|
[47]
|
Noiphithak, R. and Liengudom, A. (2017) Recent Update on Carotid Endarterectomy versus Carotid Artery Stenting. Cerebrovascular Diseases (Basel, Switzerland), 43, 68-75. https://doi.org/10.1159/000453282
|
[48]
|
Sagris, M., Giannopoulos, S., Giannopoulos, S., Tzoumas, A., Texakalidis, P., Charisis, N., Kokkinidis, D.G., Malgor, R.D., Mouawad, N.J. and Bakoyiannis, C. (2021) Transcervical Carotid Artery Revascularization: A Systematic Review and Meta-Analysis of Outcomes. Journal of Vascular Surgery, 74, 657-665.e12.
https://doi.org/10.1016/j.jvs.2021.03.032
|
[49]
|
Di Minno, A., Orsini, R.C., Chiesa, M., Cavalca, V., Calcaterra, I., Tripaldella, M., Anesi, A., Fiorelli, S., Eligini, S., Colombo, G.I., Tremoli, E., Porro, B. and Di Minno, M.N.D. (2021) Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Plate-let-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach. Biomedicines, 9, Article No. 1073.
https://doi.org/10.3390/biomedicines9081073
|
[50]
|
Basiak, M., Kosowski, M., Hachula, M. and Okopien, B. (2022) Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque. Pharmaceuticals (Basel, Switzerland), 15, Article No. 802. https://doi.org/10.3390/ph15070802
|
[51]
|
Eraikhuemen, N., Lazaridis, D. and Dutton, M.T. (2021) Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions, 21, 255- 265. https://doi.org/10.1007/s40256-020-00437-7
|
[52]
|
Ogata, A., Oho, K., Matsumoto, N., Masuoka, J., Inoue, K., Koguchi, M., Yoshioka, F. and Abe, T. (2019) Stabilization of Vulnerable Carotid Plaques with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Alirocumab. Acta Neurochirurgica, 161, 597-600. https://doi.org/10.1007/s00701-019-03825-4
|
[53]
|
Lepor, N.E., Sun, J., Canton, G., Contreras, L., Hippe, D.S., Is-quith, D.A., Balu, N., Kedan, I., Simonini, A.A., Yuan, C., Hatsukami, T.S. and Zhao, X.Q. (2021) Regression in Ca-rotid Plaque Lipid Content and Neovasculature with PCSK9 Inhibition: A Time Course Study. Atherosclerosis, 327, 31-38.
https://doi.org/10.1016/j.atherosclerosis.2021.05.008
|
[54]
|
Di Minno, M.N.D., Gentile, M., Di Minno, A., Iannuz-zo, G., Calcaterra, I., Buonaiuto, A., Di Taranto, M.D., Giacobbe, C., Fortunato, G. and Rubba, P.O.F. (2020) Changes in Carotid Stiffness in Patients with Familial Hypercholesterolemia Treated with Evolocumab®: A Prospective Cohort Study. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD, 30, 996-1004. https://doi.org/10.1016/j.numecd.2020.02.018
|
[55]
|
Marston, N.A., Gurmu, Y., Melloni, G.E.M., Bonaca, M., Gencer, B., Sever, P.S., Pedersen, T.R., Keech, A.C., Roselli, C., Lubitz, S.A., Ellinor, P.T., O’Donoghue, M.L., Giu-gliano, R.P., Ruff, C.T. and Sabatine, M.S. (2020) The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation, 141, 1600-1607. https://doi.org/10.1161/CIRCULATIONAHA.120.046397
|
[56]
|
Keech, A.C., Oyama, K., Sever, P.S., Tang, M., Murphy, S.A., Hirayama, A., Lu, C., Tay, L., Deedwania, P.C., Siu, C.W., Lira Pineda, A., Choi, D., Charng, M.J., Amerena, J., Wan Ahmad, W.A., Chopra, V.K., Pedersen, T.R., Giugliano, R.P., Sabatine, M.S. and FOURIER Study Group (2021) Efficacy and Safety of Long-Term Evolocumab Use among Asian Subjects—A Subgroup Analysis of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial. Circulation Journal: Official Journal of the Japanese Circulation Society, 85, 2063-2070. https://doi.org/10.1253/circj.CJ-20-1051
|
[57]
|
董漪. 缺血性脑卒中强化血脂管理上海专家建议[J]. 中国临床神经科学, 2022, 30(2): 121-128.
|
[58]
|
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J]. 中华神经科杂志, 2022, 55(10): 1071-1110.
https://doi.org/10.3760/cma.j.cn113694-20220714-00548
|